| __timestamp | Bristol-Myers Squibb Company | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 1244910 |
| Thursday, January 1, 2015 | 5001000000 | 5029636 |
| Friday, January 1, 2016 | 5002000000 | 4846776 |
| Sunday, January 1, 2017 | 4849000000 | 5329003 |
| Monday, January 1, 2018 | 4551000000 | 7121000 |
| Tuesday, January 1, 2019 | 4871000000 | 9128000 |
| Wednesday, January 1, 2020 | 7661000000 | 10731000 |
| Friday, January 1, 2021 | 7690000000 | 10701000 |
| Saturday, January 1, 2022 | 7814000000 | 16121000 |
| Sunday, January 1, 2023 | 7772000000 | 37021000 |
| Monday, January 1, 2024 | 8414000000 |
Igniting the spark of knowledge
In the world of pharmaceuticals, the financial strategies of companies can be as varied as their drug portfolios. Bristol-Myers Squibb Company (BMS) and Viking Therapeutics, Inc. offer a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, BMS's SG&A expenses have shown a steady increase, peaking in 2022 with a 72% rise from 2014. This reflects their aggressive market expansion and strategic acquisitions. In contrast, Viking Therapeutics, a smaller player, has seen a dramatic 2,870% increase in SG&A expenses, indicating their rapid growth and investment in market presence.
While BMS's expenses reflect a mature market strategy, Viking's surge suggests a company in the throes of expansion. Investors and analysts should consider these trends when evaluating the financial health and strategic direction of these companies.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Insmed Incorporated or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Ionis Pharmaceuticals, Inc. vs Viking Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights